Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...
2don MSNOpinion
The National Institutes of Health has been integral to scientific progress in treating countless human diseases. Without its ...
A beloved and well-known Tweed Heads mum-of-two is fighting for her life after a shock cancer diagnosis, with the community ...
NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation ...
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...
6don MSN
Trump sends Usha Vance and top security official to Greenland as PM slams ‘highly aggressive’ moves: Live - Tensions remain ...
Ms. Yumeng Wang, a member of Adagene's Board of Directors ... Adagene's highly differentiated pipeline features novel immunotherapy programs. The company's SAFEbody technology is designed to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback